Cargando…

Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma

This study set out to evaluate, in patients with metastatic colorectal carcinoma, the efficacy and toxicity of S-1, which contains tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, based on a biochemical modulation of 5-fluorouracil (5-FU) targeted at inhibition of dihydropyrimid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohtsu, A, Baba, H, Sakata, Y, Mitachi, Y, Horikoshi, N, Sugimachi, K, Taguchi, T
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2000
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363492/ https://www.ncbi.nlm.nih.gov/pubmed/10901361 http://dx.doi.org/10.1054/bjoc.2000.1236

Ejemplares similares

Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study
por: Okada, S, et al.
Publicado: (1999)

Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer
por: Punt, C.J.A., et al.
Publicado: (2023)

Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer
por: Katsumata, N., et al.
Publicado: (2011)

Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer
por: Yamada, Y, et al.
Publicado: (2008)

A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study)
por: Stebbing, J, et al.
Publicado: (2008)

Revisiting oral fluoropyrimidine with cetuximab in metastatic colorectal cancer: Real-world data in Chinese population
por: Lam, Ka-On, et al.
Publicado: (2019)

Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum
por: Yi, J H, et al.
Publicado: (2012)

Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer.
por: Lee, J. H., et al.
Publicado: (2001)

Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer
por: Leonard, R C F
Publicado: (2001)

Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis
por: Marchetti, S, et al.
Publicado: (2001)

Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues
por: Akagi, K, et al.
Publicado: (2000)

Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with RAS-mutated metastatic colorectal cancer: the REVOLUTION study protocol
por: Avallone, Antonio, et al.
Publicado: (2020)

Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer
por: Shinchi, H, et al.
Publicado: (2007)

Fatal outcome of posterior “reversible” encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen
por: Dedić Plavetić, Natalija, et al.
Publicado: (2014)

Fluoropyrimidine sensitivity of human MCF-7 breast cancer cells stably transfected with human uridinehosphorylase
por: Cuq, P, et al.
Publicado: (2001)

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
por: Yoon, D H, et al.
Publicado: (2012)

Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma
por: Yamanaka, T, et al.
Publicado: (2007)

Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study
por: Hong, R L, et al.
Publicado: (1999)

A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck
por: Couteau, C, et al.
Publicado: (1999)

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer
por: Stein, Alexander, et al.
Publicado: (2015)

Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer
por: Ichikawa, W, et al.
Publicado: (2003)

Effectiveness of oral fluoropyrimidine monotherapy as adjuvant chemotherapy for high-risk stage II colon cancer
por: Cho, Jung Rae, et al.
Publicado: (2022)

Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial
por: Tebbutt, Niall C, et al.
Publicado: (2016)

A dominant negative mutation of transforming growth factor- β receptor type II gene in microsatellite stable oesophageal carcinoma
por: Tanaka, Shinji, et al.
Publicado: (2000)

Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer
por: Kawahara, M, et al.
Publicado: (2001)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
por: Bang, Yeong Hak, et al.
Publicado: (2021)

p53 expression in squamous dysplasia associated with carcinoma of the oesophagus: evidence for field carcinogenesis
por: Yasuda, M, et al.
Publicado: (2000)

Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study
por: Douillard, J Y, et al.
Publicado: (2001)

Fluoropyrimidine-induced cardiotoxicity
por: Deac, Andrada Larisa, et al.
Publicado: (2020)

Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer
por: Koizumi, W., et al.
Publicado: (2010)

Therapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer()
por: Harada, Koji, et al.
Publicado: (2017)

MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer
por: Simmer, Femke, et al.
Publicado: (2015)

TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?
por: Petrelli, Fausto, et al.
Publicado: (2016)

The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines
por: De Mattia, Elena, et al.
Publicado: (2019)

Time trends of surgical treatment and the prognosis for Japanese patients with gastric cancer
por: Maehara, Y, et al.
Publicado: (2000)

Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer
por: Oki, Yasunari, et al.
Publicado: (2010)

Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer
por: O'Byrne, K J, et al.
Publicado: (1999)

Antitumor effects of bevacizumab in combination with fluoropyrimidine drugs on human oral squamous cell carcinoma
por: Itashiki, Yasutaka, et al.
Publicado: (2021)

Immunochemotherapy with interleukin-2, interferon- α and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study
por: Herpen, C M L van, et al.
Publicado: (2000)

Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation
por: Milano, G, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_jp3jhth5isipnrohbos7rbbq0i